Your browser doesn't support javascript.
loading
ABSTRACT
What is the role of drug interventions in the treatment of patients with covid-19? The latest version of this WHO living guidance focuses on remdesivir, following the 15 October 2020 preprint publication of results from the WHO SOLIDARITY trial. It contains a weak or conditional recommendation against the use of remdesivir in hospitalised patients with covid-19 The first version on this living guidance focused on corticosteroids. The strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19 are unchanged.
Subject(s)

Full text: Available Collection: Tematic databases Database: BIGG - GRADE guidelines Main subject: Adrenal Cortex Hormones / Anti-Retroviral Agents / COVID-19 Type of study: Practice guideline Language: English Journal: BMJ Year: 2020 Document type: Article

Full text: Available Collection: Tematic databases Database: BIGG - GRADE guidelines Main subject: Adrenal Cortex Hormones / Anti-Retroviral Agents / COVID-19 Type of study: Practice guideline Language: English Journal: BMJ Year: 2020 Document type: Article
...